A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

NCT07660172 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

BIOLOGICAL: Ianalumab
DRUG: Eltrombopag

Sponsor

Novartis Pharmaceuticals